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Abstract
 
Interferon (IFN)-
 
g
 
 and macrophages (M
 
w
 
) play key roles in acute, persistent, and latent mu-
rine cytomegalovirus (MCMV) infection. IFN-
 
g
 
 mechanisms were compared in embryonic
fibroblasts (MEFs) and bone marrow M
 
w
 
 (BMM
 
w
 
). IFN-
 
g
 
 inhibited MCMV replication in a
signal transducer and activator of transcription (STAT)-1
 
a
 
–dependent manner much more ef-
 
fectively in BMM
 
w
 
 (
 
z
 
100-fold) than MEF (5–10-fold). Although initial STAT-1
 
a
 
 activation
by IFN-
 
g
 
 was equivalent in MEF and BMM
 
w
 
, microarray analysis demonstrated that IFN-
 
g
 
regulates different sets of genes in BMM
 
w
 
 compared with MEFs. IFN-
 
g
 
 inhibition of MCMV
growth was independent of known mechanisms involving IFN-
 
a
 
/
 
b
 
, tumor necrosis factor 
 
a
 
,
inducible nitric oxide synthase, protein kinase RNA activated (PKR), RNaseL, and Mx1, and
did not involve IFN-
 
g
 
–induced soluble mediators. To characterize this novel mechanism, we
identified the viral targets of IFN-
 
g
 
 action, which differed in MEF and BMM
 
w
 
. In BMM
 
w
 
,
IFN-
 
g
 
 reduced immediate early 1 (IE1) mRNA during the first 3 h of infection, and signifi-
cantly reduced IE1 protein expression for 96 h. Effects of IFN-
 
g
 
 on IE1 protein expression
were independent of RNaseL and PKR. In contrast, IFN-
 
g
 
 had no significant effects on IE1
protein or mRNA expression in MEFs, but did decrease late gene mRNA expression. These
studies in primary cells define a novel mechanism of IFN-
 
g
 
 action restricted to M
 
w
 
, a cell type
key for MCMV pathogenesis and latency.
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Introduction
 
Murine CMV (MCMV)
 
1
 
 provides an excellent small ani-
 
mal model for the study of the immune control of 
 
b
 
-herpes
virus infection. Although many studies show the impor-
tance of the IFN system, and specifically IFN-
 
g
 
, in con-
trolling MCMV infection both in vivo (1–10) and in vitro
(7, 9, 11–15), the mechanisms by which IFN-
 
g
 
 regulates
CMV infection remain largely undefined. In addition to
studies consistent with IFN-
 
g
 
 inhibiting MCMV replica-
 
tion
 
 
 
in vivo, we showed that IFN-
 
g
 
 inhibits reactivation of
MCMV from latently infected explants of spleen and lung
(7), which is consistent with the finding that reactivation
 
 
 
in
vivo is enhanced by treating with Abs to IFN-
 
g
 
 (10). Mice
lacking the IFN-
 
g
 
 receptor develop chronic MCMV-asso-
ciated large vessel vasculitis, demonstrating the importance
of IFN-
 
g
 
 in regulating chronic CMV disease (7). Effects on
reactivation from latency in tissue explants are due at least
in part due to a blockade of growth from low levels of virus
in primary cells (7), suggesting that defining mechanisms of
IFN-
 
g
 
 antiviral action in primary cells will be critical to
understanding how IFN-
 
g
 
 plays such a pivotal role in mul-
tiple stages of MCMV infection.
Identification of specific stages in viral replication
blocked by IFNs has historically been critical to defining
the molecular mechanisms of IFN action. Despite the im-
portance of IFN-
 
g
 
 
 
in vivo, there is some conflict in the lit-
erature regarding the stage in the viral life cycle at which
IFN-
 
g
 
 blocks MCMV replication in fibroblasts, and other
cell types have not been investigated. One study showed
that IFN-
 
g
 
 inhibits expression of MCMV immediate early
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Abbreviations used in this paper: 
 
BM, bone marrow; EMSA, electro-
phoretic mobility shift assay; HBV, hepatitis B virus; HCMV, human
CMV; IE, immediate early; iNOS, inducible nitric oxide synthase;
 
MCMV, murine CMV; MEF, murine embryonic fibroblast; M
 
w
 
, mac-
rophage; MOI, multiplicity of infection; PKR, protein kinase RNA acti-
vated; STAT, signal transducer and activator of transcription. 
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w
 
transcripts (IE) in 3T3 cells (13), but another study in pri-
mary embryonic fibroblasts found that IFN-
 
g
 
 blocked a
late phase of MCMV infection (11). In addition to our lack
of understanding of the specific targets of IFN-
 
g
 
 action
against MCMV in primary cells, it is not known how cur-
rently defined mechanisms involving protein kinase RNA
activated (PKR), RNaseL, Mx1, the IFN-
 
a
 
/
 
b
 
 receptor,
TNF-
 
a
 
 receptors (TNFR1 or TNFR2), inducible nitric
oxide synthase (iNOS), or Mx1 (for reviews, see references
16–18) influence IFN-
 
g
 
 action against MCMV.
To define the molecular mechanisms of IFN-
 
g
 
 action,
we studied its effects on two primary cell types, murine
embryonic fibroblasts (MEFs) and bone marrow–derived
macrophages (BMM
 
w
 
). MEFs have traditionally been the
cell type in which MCMV is propagated in vitro (19).
Macrophages (M
 
w
 
) are an important cell in the pathogene-
sis of MCMV infection during both acute and latent infec-
tion, both stages at which IFN-
 
g
 
 has an important role.
M
 
w
 
 play a key role during acute infection as mediators of
spread of the virus (20–23), as a predominant cell in inflam-
matory infiltrates occurring during MCMV infection
(9,24), and as a cell type that can determine the outcome of
in vivo infection (25, 26). M
 
w
 
 are critical to MCMV la-
tency as a site of latent infection (27–29).
We found that IFN-
 
g
 
 has an M
 
w
 
-restricted, IFN-
 
g
 
 re-
ceptor and signal transducer and activator of transcription
(STAT)-1
 
a
 
–dependent, mechanism of action independent
of PKR, RNaseL, Mx1, IFN-
 
a
 
/
 
b
 
 receptor, TNFR1,
TNFR2, and iNOS. In BMM
 
w
 
, IFN-
 
g
 
 targets the
MCMV IE1 gene product, a key regulator of CMV gene
expression (30–32).
 
Materials and Methods
 
Cells, Virus, and Viral Assays.
 
BMM
 
w 
 
and MEFs were differ-
entiated and maintained in low endotoxin medium containing
10% FCS, and used at passage one or two, respectively (24, 27).
The differentiation state of these cells has been described previ-
ously (33, 34, and references therein). Unless otherwise indicated,
BMM
 
w
 
 and MEFs were derived from BALB/c mice. MCMV
Smith strain was obtained from the American Type Culture Col-
lection (no. VR-194, Lot 10), grown in 3T12 cells, and quanti-
tated by plaque assay (9). MEFs and BMM
 
w
 
 were plated in
6-well tissue culture–treated plates (Falcon) at 2.5 
 
3
 
 10
 
5
 
 cells/
well with or without IFN-
 
g
 
 (Genzyme). After 48 h, cells were
infected at a multiplicity of infection (MOI) of 0.001 to 30 for 1 h
at 37
 
8
 
C, washed twice with medium, and cultured in 1.5 ml of
medium. At the times indicated, plates were frozen at 
 
2
 
70
 
8
 
C and
titered by plaque assay. For limiting dilution analysis, immunoflu-
orescence, and Northern and Western analysis, cells were treated
with or without 100 U/ml IFN-
 
g
 
 for 48 h, washed with PBS-
EDTA (Sigma-Aldrich), and scraped (BMM
 
w
 
) or detached with
trypsin (MEF), counted, centrifuged, and resuspended in a mini-
mal volume of medium (generally 1 ml/10
 
7
 
 cells) before infection
at an MOI of 1 for 2 h on ice.
 
Limiting Dilution Analysis.
 
Infected BMM
 
w
 
 or MEFs were
cultured for 2 h at 37
 
8
 
C to allow for internalization; washed 2–3
times with 10 ml media, harvested, and serially diluted twofold
from 2 
 
3
 
 10
 
3
 
 cells/well into 96-well plates (24 wells/dilution/
experiment). MEFs were added (5 
 
3
 
 10
 
3
 
 cells/well) as indicator
 
cells for cytopathic effect (cpe). Cultures were scored for cpe at 2
and 3 wk after infection. This assay has a sensitivity of about 1
PFU/well (7, 35).
 
Immunofluorescence for IE1 Expression.
 
BMM
 
w
 
 were plated
onto 8-well Lab-Tek Glass Chamber slides (Nunc), cultured on
the slides for 12 h, washed with PBS, and fixed with 1%
paraformaldehyde in PBS for 20 min at room temperature. Cells
were incubated overnight in blocking buffer containing 2% BSA
(Sigma-Aldrich), and 10% each normal rabbit serum (Sigma-
Aldrich) and goat serum (GIBCO BRL) in PBS. Immunofluores-
cence was performed using culture supernatant derived from the
anti-IE1–specific mAb line Croma (donated by M. Messerle,
Ludwig-Maximilians-Universitat Munchen, Munich, Germany)
or an isotype-matched IgG1 control mAb HI-gamma-1-109.3
specific for DNP (0.01 
 
m
 
g/ml; reference 36) for 1 h at 4
 
8
 
C. Cells
were then stained with FITC-conjugated goat anti–mouse IgG
and IgM at 1:200 (Tago) in blocking buffer for 1 h at 4
 
8
 
C, and
counterstained with bisbenzimide. Cells were coverslipped with
PBS-glycerol and kept in the dark at 4
 
8
 
C until viewing. Slides
were viewed on a ZEISS Axiophot Microscope and pictures
taken with a Spot CCD camera using Northern Eclipse software
(Empix Imaging). Blue bisbenzimide staining was converted to
the red plane for ease of visualization of dual stained slides.
 
Northern Blot Analysis.
 
RNA was harvested at the indicated
times as described (37, 38), size fractionated on a 1.5% denaturing
gel, and transferred to nylon membranes (Hybond-N; Amer-
sham Pharmacia Biotech). Probes for IE1, DNA polymerase
(DNApol), or glycoprotein B (gB) were generated by PCR, us-
ing plasmid pAMB25 for IE1 (39) and the HindIII D fragment of
the MCMV genome for DNApol and gB as template DNA (40).
Primers for PCR were: IE1, GGGGAATGATAACAGC-
GACA/ATCCAGACTCTCTTTTCTGAGG; DNApol, GTG-
GCGTGTTGTATGATGGT/CTGGTCGTAGGTGTGGA-
AGC; gB (nested PCR), outer primers, CAGCCTGGAC-
GAGATCAT/TCCTCGCAGCGTCTCCAATC, inner prim-
ers, CGTGTATCTCATCTTCACGAG/AGTGTCCATGTC-
GGCCGTCA (23). Each PCR reaction contained: 50 mM KCl,
10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM
MgCl
 
2
 
 (for IE1 and gB) or 1.5 mM MgCl
 
2
 
 (for DNApol), 0.2
mM nucleotides, 0.15 
 
m
 
M each primer, and 1 U Taq (Ther-
mus aquaticus) DNA polymerase. PCR was performed on a
Temp Tronic thermocycler (Barnstead/Thermolyne) for 35
cycles. Annealing temperatures were: 59.5
 
8
 
C for IE1 and 55
 
8
 
C
for DNApol and gB. The probe for E1 was a 484-bp Pst1/
Xho1 fragment from a 5.5-kb Pst1 fragment from the MCMV
HindIII F region (40). The probe for cyclophilin was a 680-bp
BamH1/HindIII fragment of pSP65 containing the rat cyclo-
philin gene (41). Probes were radiolabeled with [
 
32
 
P]dCTP
(MegaPrime DNA labeling system; Amersham Pharmacia Bio-
tech), and hybridization signals were quantified by Phosphor-
Imager (ImageQuant; Molecular Dynamics) and normalized to
cellular cyclophilin.
 
Western Blot Analysis.
 
Western analysis was performed as de-
scribed (42). Generally, 2–3 
 
3
 
 10
 
6
 
 cells were lysed directly in 0.5
ml of Laemmli sample buffer, frozen at 
 
2
 
70
 
8
 
C, boiled for 5 min,
and then 5 
 
m
 
l was run on a 12.5% polyacrylamide gel with a 5%
stacking gel. Gels were transferred and then blotted using super-
natant derived from the Croma cell line producing anti-IE1
mAB, or the anti-E1 mAb 20-234-28 (31), or anti–
 
b-actin mAb
AC-74 (used at 1:1,000; Sigma-Aldrich). IE1 has two isoforms
(pp89 and pp72; references 43 and 44), both of which are de-
tected by the Croma anti-IE1 mAB. A horseradish peroxidase–
conjugated goat anti–mouse secondary was used (1:1,000; Tago),485 Presti et al.
and membranes were developed using ECL Western Blotting
Detection Reagents (Amersham Pharmacia Biotech). Protein
quantitation was performed by comparing net intensity of pre-
dominant bands using Kodak ds1D software after photography on
a DC120 camera (Eastman Kodak Co.).
Mice Used in These Studies. All mice were housed in a Bio-
safety Level 2 facility at Washington University in accordance
with all federal and university policies. BALB/c mice were from
the National Cancer Institute, and C57BL/6 mice were from the
The Jackson Laboratory. All other strains were bred at Washing-
ton University. STAT-1a–deficient mice (STAT-1a2/2) and
TNF double receptor knockout mice (TNFR1R22/2) were ob-
tained from Dr. R. Schreiber (Washington University School of
Medicine, St. Louis, MO; reference 45–47). 129 Sv/Ev mice and
mice with null mutations in the IFN-g receptor (IFN-gR2/2) or
IFN-a/b receptor (IFN-a/bR2/2) were obtained from Dr. M.
Aguet (Swiss Institute for Experimental Cancer Research,
Epalinges, Switzerland; reference 48). Mice deficient in iNOS
(iNOS2/2) were obtained from Dr. C. Nathan (Cornell Univer-
sity, New York, NY; reference 49). Mice deficient in RNase L
(RNaseL2/2) were obtained from Dr. R. Silverman (Cleveland
Clinic Foundation, Cleveland, OH; reference 50). Mice deficient
in PKR (PKR2/2) were obtained from Dr. B. Williams (Cleve-
land Clinic Foundation, Cleveland, OH; reference 51).
Electrophoretic Mobility Shift Assays for STAT-1a Activation.
1.5–2  3 106 cells per sample were treated with concentrations of
IFN-g noted in text for 15 min at 378C, and nuclear extracts
were prepared as described (34). Samples were normalized ac-
cording to cell number. 20% of each extract was assayed by elec-
trophoretic mobility shift assay (EMSA) against a probe derived
from the IFN-g–activating sequence of the FcgR1 promoter
(52). After acrylamide gel electrophoresis (6%), gels were dried
and quantified by PhosphorImager (ImageQuant). To combine
data from four independent experiments, PhosphorImage values
were normalized by setting the highest value to one and lowest
value to zero (GraphPad Prism) and results were averaged.
Microarray Analysis. BMMw and MEF from IFN-a/bR2/2
mice were mock infected for 1 h followed by treatment with or
without 100 U/ml of IFN-g for 48 h. RNA was harvested as
above. Poly A purification, generation of cDNA, fluorescent la-
beling, and hybridization to gene chip were performed by Ge-
nome Systems essentially as described (53). 8,717 mouse genes
were analyzed on Mouse GEM 1 (Incyte Pharmaceuticals, Inc.)
microarrays using the software GEMtool 2.4.1.
Results
IFN-g Pretreatment Inhibits Growth of MCMV in Mw and
MEFs. Pretreatment for 48 h with IFN-g caused a dose-
dependent inhibition of MCMV growth in both BMMw
(Fig. 1 A) and MEFs (Fig. 1 B). Growth inhibition was
more significant in BMMw than MEFs. BMMw showed a
.100-fold decrease in viral titer by 72 h after infection (for
example, at 100 U/ml of IFN-g), whereas MEFs showed a
maximum decrease of 5–10-fold even at 1,000 U/ml of
IFN-g. These results are consistent with other studies of
IFN-g effects on the growth of MCMV in fibroblasts (11,
13) and demonstrate an antiviral effect of IFN-g in primary
BMMw.
As lower final titers of virus were produced in untreated
BMMw than untreated MEF at an MOI of 1 (Fig. 1, A and
B), we tested the hypothesis that the difference in effective-
ness of IFN-g treatment between the two cell types was
due to inefficient MCMV replication in Mw by treating
BMMw or MEFs with IFN-g, and then infecting at a vari-
ety of MOIs (0.001–30; Fig. 1 C and data not shown). As
we increased the MOI in untreated BMMw, the yield of
MCMV increased to levels equivalent to or higher than
those seen in untreated MEFs, without a decrease in the ef-
fect of IFN-g (Fig. 1 C). The efficacy of IFN-g in fibro-
blasts increased somewhat at an MOI of 0.1, a finding con-
sistent with previous literature (7, 11, 13). However, we
examined the relative efficacy of IFN-g in BMMw and
MEFs at MOIs of 0.01 and 0.001 and found that IFN-g
was consistently more effective at controlling MCMV
growth in BMMw than MEFs (two- to fivefold in three in-
dependent experiments, not shown). We also considered
the possibility that IFN-g might be more effective in
BMMw via induction of cell death, but found no decrease
in BMMw viability with or without IFN-g in the presence
or absence of MCMV at 8 and 24 h after infection (data
not shown, three independent experiments). These data
showed cell type specificity of IFN-g action, with IFN-g
Figure 1. IFN-g pretreatment inhibits growth of MCMV more effec-
tively in BMMw than MEFs. (A and B) BMMw (A) or MEFs (B) were
treated with or without IFN-g for 48 h, infected at an MOI of 1, and
cultured for the indicated times before freeze-thawing and plaque assay.
Data shown is representative of two (BMMw) or three (MEF) indepen-
dent experiments. Analysis of data in MEFs (B) revealed that the effects of
IFN-g were significant at 100 U/ml (48 h, P 5 0.0231; 72 h, P 5 0.02),
and 1,000 U/ml (72 h, P 5 0.0091), but that all other differences were
insignificant (P . 0.05). (C) To determine the effect of MOI on IFN-g
treatment, BMMw or MEFs were treated with or without 100 U/ml
IFN-g for 48 h, infected at the MOIs shown, and cultured for 72 h be-
fore freeze-thawing and plaque assay (mean 6 SEM from two indepen-
dent experiments).486 Cell Type–specific IFN-g Antiviral Mechanism in Mw
being more effective at inhibiting MCMV growth in
BMMw than in MEFs across a broad range of IFN doses,
times after infection, MOIs, and regardless of the final yield
of virus.
Mediators of IFN-g Inhibition of MCMV Replication in
BMMw. Mw secrete molecules which may synergize with
IFN-g or provide their own protective effects including:
(a) IFN-a/b, (b) TNF-a, and (c) nitric oxide (NO; refer-
Figure 2. TNF-a, iNOS, IFN-a/b, PKR, and RNase
L are not required for IFN-g inhibition of MCMV repli-
cation in BMMw. BMMw were prepared from BALB/c
(A), 129 (B), C57/Bl6 (C), TNFR1/TNFR22/2 (D),
iNOS2/2 (E), IFN-a/bR2/2 (F), PKR2/2 (G) or
RNaseL2/2 (H) mice. Cells were treated with or without
100 U/ml IFN-g for 48 h, infected at an MOI of 1, and
cultured for the indicated times before freeze-thawing and
plaque assay (mean 6 SEM from two to six independent
experiments).
Figure 3. Secreted mediators from IFN-g–treated wild-type BMMw
do not protect IFN-g unresponsive BMMw. (A) BMMw from IFN-
gR2/2 mice and wild-type mice were treated with or without 100 U/ml
of IFN-g, infected at an MOI of 1, and cultured for the indicated times
before freeze-thawing and plaque assay (mean 6 SEM from three inde-
pendent experiments). Data is shown for IFN-gR2/2 BMMw only.
IFN-g efficiently inhibited MCMV growth in wild-type BMMw (not
shown, see Fig. 1). (B and C) BMMw from wild-type (Balb or 129; B) or
IFN-gR2/2 (C) mice were treated for 48 h with medium, medium plus
100 U/ml IFN-g, or supernatant from IFN-g (100 U/ml)–treated wild-
type BMMw. BMMw were then infected at an MOI of 1 and cultured
for the indicated times before freeze-thawing and plaque assay (mean 6
SEM from three independent experiments). (D) Wild-type (wt; BALB/c
or 129), IFN-gR2/2 or a 50:50 mix of wild-type and IFN-gR2/2
BMMw were plated and treated with or without 100 U/ml IFN-g for 48 h,
infected at an MOI of 1 and cultured for the indicated times before
freeze-thawing and plaque assay (mean 6 SEM from two independent
experiments). Results from the IFN-g–treated cultures are shown. Re-
sults from cultures lacking IFN-g were superimposable to the IFN-g–
treated IFN-gR2/2 BMMw and are not shown.
Figure 4. STAT-1a activation is required for IFN-g inhibition of
MCMV growth, but differences in early STAT-1a activation does not
explain the cell type specificity of IFN-g action. (A) STAT-1a2/2
BMMw were treated with or without 100 U/ml IFN-g for 48 h, infected
at an MOI of 1, and cultured for the indicated times before freeze-thaw-
ing and plaque assay (mean 6 SEM from two independent experiments).
IFN-g efficiently inhibited MCMV replication in concurrent cultures of
wild-type 129 BMMw (not shown). (B and C) Cells were stimulated with
IFN-g at the indicated doses for 15 min at 378C, nuclear lysates were pre-
pared, and EMSA performed using a probe derived from the FcgRI
gamma response region. One representative (of four) experiment is
shown in (B). Quantitation of STAT-1a activation by PhosphorImage
analysis is shown in C (mean 6 SEM for four independent experiments).487 Presti et al.
ences 11 and 54–60). These molecules were not required
for IFN-g action in BMMw, as IFN-g efficiently inhibited
MCMV growth in BMMw derived from mice with null
mutations in genes encoding the IFN-a/b receptor (IFN-
a/bR2/2), both TNF-a receptors (TNFR1/R2/2), or
iNOS (Fig. 2).
To assess the possible role of novel IFN-g–induced solu-
ble mediators, we first demonstrated that IFN-g action re-
quires expression of the IFN-g receptor (Fig. 3 A), and
then determined whether IFN-g treated wild-type BMMw
secrete a mediator that inhibits growth of MCMV in IFN-
gR2/2 BMMw. Supernatant from IFN-g–treated wild-
type Mw (derived from 129 or BALB/c mice) did not pro-
tect IFN-gR2/2 BMMw, although wild-type Mw were
protected (Fig. 3, B and C). Thus, IFN-g treatment did not
induce a stable molecule that can inhibit MCMV replica-
tion in IFN-gR2/2 cells. To rule out contributions of
unstable mediators, we determined whether wild-type
BMMw can protect IFN-gR2/2 cells when the cells are
cocultured. Wild-type BMMw were not able to protect
IFN-gR2/2 BMMw in these cultures (Fig. 3 D). This ex-
periment argues against a secretion of a IFN-g–induced
mediator responsible for the antiviral state of BMMw, but
must be caveated with the possibility that such a mediator
was induced, but also requires IFN-g induction of its re-
ceptor. Together with data in BMMw lacking known se-
cretion-dependent antiviral mechanisms (Fig. 2), these data
argue that IFN-g acts in BMMw by inducing intracellular
changes that result in decreased viral yield.
Three effector mechanisms for IFN action that involve
changes in intracellular molecules have been identified:
29,59 oligoadenylate synthetase (OAS), PKR, and Mx1 (for
reviews, see references 16 and 17). BALB/c mice, the strain
used for the majority of the experiments above, are defi-
cient in Mx1 (61, 62), and therefore this pathway was not
responsible for IFN-g effects in BMMw. To test the other
pathways, we used BMMw deficient in RNaseL (50), the
only known downstream effector of activated OAS, or in
PKR (51). IFN-g effectively controlled MCMV replication
in PKR2/2 and RNaseL2/2 BMMw (Fig. 2, G and H).
STAT-1a Activation Is Essential for IFN-g Effects in BM-
Mw, but STAT-1a Activation Is Similar in BMMw and
MEFs. The latent cytoplasmic transcription factor STAT-
1a is a proximal signaling molecule essential for IFN-g an-
tiviral effects against vesicular stomatitis virus (VSV) in cell
lines and in vivo (45, 63). Using BMMw from mice with a
null mutation in the STAT-1a gene (45), we found that
the antiviral effect of IFN-g was completely dependent on
Figure 5. Comparative expression of transcripts in BMMw and MEFs af-
ter IFN-g treatment. (A) Scatter plot of fluorescence intensity comparing
gene expression in BMMw with or without IFN-g treatment for 8,717
genes. The Cy5 and Cy3 signal values indicate the amount of transcript
measured in BMMw plus IFN-g and BMMw plus media treatment only,
respectively. (B) The data is plotted for MEFs as in A with Cy5 and Cy3 signal values indicating the amount levels of transcripts in MEF plus IFN-g and
MEF plus media treatment only, respectively. (C and D) Bar graphs showing the expression of 49 genes which were changed more than fivefold by IFN-g
treatment in either (C) BMMw or (D) MEF samples. These genes are ordered identically in C and D. The lowercase letters represent groupings of tran-
scripts with different expression patterns and are described in the text and Table I. The genes are listed in Table I. The limit of statistical significance is set
at twofold based on data from Incyte Genomics analyzing the variance in the method across multiple experiments.488 Cell Type–specific IFN-g Antiviral Mechanism in Mw
Table I. List of All Genes Changed Fivefold or More by IFN-g Treatment to Accompany Fig. 5, C and D
Category
GenBank
accession no. Gene name or product
Fold change in BMMw
versus BMMw plus IFN-g 
Fold change in MEF versus
MEF plus IFN-g 
a: Specifically  AA163727 ZW1- homolog (Drosophila), centromere/kinetochore protein 25.9 21.2
down in BMMw AA276440 Selenoprotein P, plasma, 1 25.8 1.3
W59165 Folate binding protein 2 25.8 21.1
AA138966 EST 25.2 1.1
b: Specifically  AA058055 EST 21.4 25
down in MEF AA030821 EST 21.2 25
AA008052 EST 21.2 25.2
W14275 EST 1 26.1
W85641 EST 1.1 25.3
AA175695 EST 1.1 26.2
W63822 Homeo box A2 1.1 26.4
W14332 EST 1.2 25.2
AA390032 EST 1.2 25.8
W97155 EST 1.2 26.1
AA216849 EST 1.3 25.9
AA538511 Histocompatibility 2, D region locus 1* 2.8 27.6
AA240404 Putative purine nucleotide binding protein mRNA* 2.9 28.9
c: Specifically AA245029 EST 21.1 6
up in MEF AA209006 EST 1 6.7
d: Specifically  AA217290 EST 5.3 1.6
up in BMMw AA177481 EST 5.5 21.3
AA458171 EST 5.6 1.6
AA230649 Histocompatibility 2, class II, locus DMa* 5.9 1.9
AA269724,
AA277329 H-2 class II histocompatibility antigen, I-A b chain precursor* 7.3 1.5
AA462202 BP-3 alloantigen 9.1 1.5
W34612 Transglutaminase 2, C polypeptide 10 1.1
e: Upregulated  AA186012 Histocompatibility 2, Q region locus 7* 3 5.6
in BMMw AA177731 EST 3.3 5.2
and MEF AA143986 EST 3.8 5.9
AA109951 b2 microglobulin* 4.5 9.1
AA140542 EST 4.7 14.2
AA138757 EST 5.4 13.2
AA451385 EST 5.4 3.7
AA174721 EST 5.5 11
AA286393,
AA172456 Small inducible cytokine A12 5.9 4.2
AA123837 Transporter 1, ABC (ATP binding cassette) 6.2 3.1
AA388678 STAT 1 6.4 5.1
AA475774 Cathepsin C* 6.6 3.2
AA272807 Histocompatibility 2, class II antigen A, alpha* 7.5 4.6
AA172624 EST 8.9 14.1
AA145136 EST 8.9 16.1
AA260490 EST 9.1 8.3
AA204588 EST 9.5 15.4
AA122443 EST 11 11.6
AA472492 Monokine induced by IFN-g* 14.9 12.5
AA153021,
AA277451
IFN-induced guanylate binding
protein* 19.8 21.3
W83447,
AA210495 Spi2 proteinase inhibitor (spi2/eb1) 30.1 7.8
AA000712,
AA472994
AA145865 Lymphocyte antigen 6 complex* 46.2 12.5
GenBank accession numbers, gene names, and fold changes in gene expression are listed from top to bottom in the same order as left to right in Fig. 5, C and D, for all
genes changed more than fivefold in either MEFs or BMMw by IFN-g treatment. The lower case letters in the left column correspond to those in Fig. 5, C and D.
*Genes previously shown to be induced by IFN-g.489 Presti et al.
STAT-1a (Fig. 4 A). We therefore tested the hypothesis
that lack of effective STAT-1a activation in MEF explains
the lack of effective IFN-g action against MCMV in these
cells (Fig. 1) using EMSA (Fig. 4, B and C). We used a
probe derived from the IFN-g–activated sequence of the
FcgRI promoter shown by supershift analysis to be STAT-
1a specific in primary BMMw (34, 52). STAT-1a activa-
tion was similar between MEF and BMMw across a range
of IFN-g doses, demonstrating that the proximal signaling
cascade for IFN-g is intact in both cell types (Fig. 4 B).
Near maximal STAT-1a activation was seen with IFN-g
doses of 10 U/ ml, and STAT-1a activation was maximal
in both MEF and BMMw at a dose of 100 U/ml. Thus, the
difference in effectiveness of IFN-g at inhibiting MCMV
replication in MEFs and BMMw observed between 10 and
1,000 U/ml of IFN-g (Fig. 1, A and B) cannot be ex-
plained by different proximal signaling events in these two
cell types.
Cell Type–specific Regulation of Genes in MEFs Versus
BMMw Defined by Microarray Analysis. Although STAT-
1a activation was similar in BMMw and MEF (Fig. 4), the
differences in IFN-g effectiveness at inhibiting MCMV
growth suggested that IFN-g effects differ between MEFs
and BMMw. We therefore performed microarray analysis
to compare levels of 8,717 mouse genes 48 h (the time at
which we infect with MCMV) after IFN-g treatment of
MEFs and BMMw (Fig. 5). IFN-g had less than twofold
effects on the vast majority of genes in either MEFs or
BMMw at the 48-h time point (Fig. 5, A and B). However,
49 genes, many previously known to be induced by IFN-g,
were changed more than fivefold in BMMw and/or MEF
(Fig. 5, C and D, and Table I).
IFN-g–induced changes in gene expression differed be-
tween MEFs and BMMw. These differences included genes
whose expression was either increased or decreased in
BMMw but not altered in MEFs (groups a and d, Fig. 5, C
and D, and Table I), and genes whose expression was either
increased or decreased in MEFs but not altered in BMMw
(groups b and c, Fig. 5, C and D, and Table I). There was a
group of genes whose expression was increased in both
MEFs and BMMw, and these include several genes well
known to be IFN inducible (group e, Fig. 5, C and D, and
Table I). This data showed that despite similarities in
STAT-1a activation, there are significant differences in
IFN-g effects in MEFs versus BMMw, providing a ratio-
nale for the differences in IFN-g effectiveness at control-
ling MCMV growth in these two cell types.
IFN-g Decreases Viral Yield per Infected BMMw. To de-
termine why IFN-g is more effective at controlling
MCMV growth in BMMw than MEFs, we analyzed the
Figure 6. IFN-g inhibits MCMV replication in both BMMw and MEFs by decreasing viral yield per cell rather than decreasing the number of infected
cells. (A) BMMw or MEFs were treated with or without 100 U/ml IFN-g for 48 h, infected at an MOI of 1 for 2 h on ice, and then incubated for 2 h at
378C to allow internalization of the virus. Cells were washed, serially diluted, and the frequency of productively infected cells determined. Data shown is
the percentage of wells with cytopathic effect (24 wells/dilution/experiment) from one of two experiments with similar results. (B–D) BMMw were
treated with medium (B) or 100 U/ml IFN-g (C), infected at an MOI of 1 for 1 h at 48C, or mock infected. Cells were stained with an IE1-specific mAb
(B and C) or an isotype-matched control mAb (D), a FITC-conjugated secondary Ab, and counterstained with bisbenzimide. Data shown are double ex-
posures of bisbenzimide staining (converted from the blue to red plane) and FITC staining. IE1-positive cells can be visualized as light yellow nuclei.
Shown is a representative one of four experiments. For this experiment shown, two independent, randomly selected regions of each of two slides for each
condition were photographed and counted. 21% (252 of 1,206 cells counted) of media-treated BMMw (B) expressed nuclear IE1 protein, whereas 17%
(136 of 792 cells counted) of IFN-g–treated BMMw (C) expressed nuclear IE1 protein. Infected cells stained with the isotype-matched mAb, HI-
gamma-1-109.3 specific for DNP, were uniformly red (shown are IFN-g–treated infected BMMw (D). Mock-infected cells stained with either mAb spe-
cific for IE1 or control mAB were indistinguishable from D.490 Cell Type–specific IFN-g Antiviral Mechanism in Mw
effect of IFN-g on sequential stages in the MCMV replica-
tion cycle in MEFs and BMMw. We first determined the
frequency of cells productively infected with MCMV using
limiting dilution analysis and a MEF indicator monolayer
previously shown to detect 1–10 PFU of MCMV even in
the presence of IFN-g (7, 35). IFN-g did not alter the fre-
quency of productively infected MEFs (Fig. 6 A). How-
ever, 100 U/ml of IFN-g decreased the frequency of pro-
ductively infected BMMw two- to fourfold (Fig. 6 A). In
the absence of an IFN-g–induced decrease in MCMV
yield per infected cell, this difference would not explain the
100-fold decline in MCMV titer caused by the same dose
of IFN-g in BMMw (Fig. 1). We next quantitated IFN-g
effects on the frequency of BMMw expressing the IE1 pro-
tein by immunofluorescence. IFN-g did not significantly
change the frequency of BMMw expressing the IE1 protein
(Fig. 6). This ruled out significant effects of IFN-g on viral
binding, internalization, and the frequency of cells express-
ing IE1 protein as an explanation for the antiviral effects of
IFN-g in BMMw. However, we did notice that immu-
nofluorescent staining for IE1 was qualitatively fainter in
IFN-g–treated than control BMMw (see below). Results
from limiting dilution analysis and staining for IE1 protein
demonstrated that IFN-g effects on MCMV titer were due
to changes in the frequency of productively infected cells
and viral yield per infected cell.
IFN-g Inhibits Expression of the MCMV IE1 mRNA dur-
ing the First 3 h of Infection in BMMw but Not MEF. We
next examined whether steady-state levels of message from
representative IE, early, or late genes were influenced by
IFN-g treatment. IFN-g treatment of BMMw decreased
expression of IE1 mRNA z10-fold at 1–2 h after infection
(Fig. 7 A). By 4 h and thereafter, levels of IE1 mRNA dif-
fered by at most twofold between BMMw treated with
IFN-g or medium alone (Fig. 7 A, quantitation shown in
Fig. 7 B). Early and late transcript levels were also decreased
by IFN-g treatment in Mw (Fig. 7 A). DNA polymerase
was decreased 3–13-fold (across five experiments) and gly-
coprotein B levels were decreased 5–10-fold (across five ex-
periments). In contrast to results in BMMw, levels of IE1
mRNA were unchanged by IFN-g treatment in MEFs (Fig.
7 A). In MEFs there was a slight effect of IFN-g on mRNA
levels for one early gene, DNA polymerase, but not for an-
other early gene, E1. Consistent with a previous report (11),
the most dramatic effect in MEFs was seen on the level of
late gene transcripts as assessed by glycoprotein B (Fig. 7 A).
IFN-g Inhibits Expression of IE1 Protein for Prolonged Peri-
ods in BMMw but Not MEFs. As IFN-g significantly in-
hibited early and late gene expression in BMMw, but had
relatively subtle effects on IE1 mRNA expression after 4 h
(Fig. 6 B), we considered the possibility that IFN-g inhib-
ited the expression of IE proteins (Fig. 8 A), which are crit-
ical regulators of early and late gene expression (30–32).
IE1 (the pp89 isoform [43, 44], see Materials and Meth-
ods, referred to as IE1 here) and E1 protein expression was
not altered by IFN-g in MEFs. The decrease in IE1 ex-
pression seen at 8 and 12 h seen in both IFN-g–treated and
control MEFs samples has been described previously and is
part of the normal viral replication cycle (44). There was
no effect of IFN-g or virus infection on actin levels, dem-
onstrating that the effect of IFN-g on IE1 protein expres-
sion was not due to a general degradation of protein in
IFN-g–treated cells.
Surprisingly, although there was no detectable effect of
IFN-g on the protein level of IE1 or E1 in MEFs, there
Figure 7. IFN-g alters steady
state levels of different viral tran-
scripts in MEFs compared with
BMMw. (A) BMMw or MEF
were treated with or without
100 U/ml IFN-g for 48 h, in-
fected at an MOI of 1, and at the
times indicated Northern analysis
was performed using probes di-
rected to the viral IE gene, IE1;
the viral early genes, E1 and
DNA pol; or the viral late gene,
gB. Cyclophilin expression is
shown as a loading control.
Shown are representative results
from one of five (BMMw) or
one of three (MEF) experiments.
(B) Phosphorimage quantitation
of mRNA levels of IE1 message
levels in media-treated or IFN-
g–treated BMMw was used to
determine the fold decrease in
message levels in IFN-g–treated
cells. Fold decrease is expressed
as the amount of IE1 message in
media-treated BMMw divided
by the amount in IFN-g treated
BMMw (mean 6 SEM of two to
six independent experiments).
Figure 8. IFN-g decreases
expression of IE1 protein in
BMMw but not MEFs. (A)
BMMw or MEFs were treated
with or without 100 U/ml IFN-g
for 48 h, infected at an MOI of
1, and at the times indicated
Western analysis was performed
with mAb directed against the
viral IE protein, IE1, or the viral
early protein, E1. b-actin is
shown as a loading control.
Shown are representative results from one of three experiments. (B) Net
intensity measurements on ECL-developed Western blots were used to
quantitate the fold decrease of IE1 protein levels in IFN-g–treated
BMMw compared with media-treated BMMw (mean 6 SEM from three
independent experiments).491 Presti et al.
was a significant decrease (z6–24-fold in four experiments
at all times from 3–24 h after infection) in IE1 and E1 pro-
tein levels in IFN-g–treated BMMw (Fig. 8 A, quantitation
shown in Fig. 8 B). There was also a decrease (about sixfold
across six experiments) in the pp72 isoform of IE1 in
BMMw and a smaller decrease of about two- to threefold
in MEFs. The decrease in IE1 protein expression in
BMMw persisted for 96 h after infection (data not shown).
It was notable that the fold decrease in IE1 protein caused
by IFN-g was significantly greater than the fold decrease in
IE1 mRNA at multiple time points after 3 h (compare Figs.
7 B and 8 B). Differences in IE1 expression between
BMMw and MEFs were not MOI dependent. IE1 protein
expression at 8 and 24 h after infection was not significantly
inhibited in MEFs infected at MOIs ranging from 1 to
0.001 (data not shown, three independent experiments).
We considered the possibility that effects of IFN-g on
IE1 protein or RNA expression were due to known medi-
ators of IFN action RNaseL and PKR, despite the fact that
these molecules were not required for IFN-g–mediated in-
hibition of MCMV replication (Fig. 2). It was possible that
IFN-g–mediated inhibition of IE1 protein expression was
dependent on PKR, as PKR phosphorylates EIF2a,
thereby inhibiting protein synthesis (64). It was also possi-
ble that activation of RNaseL might contribute to alter-
ations in IE1 mRNA expression induced by IFN-g treat-
ment. Therefore, we examined mechanisms of IFN-g
action in more detail in PKR2/2 and RNaseL2/2 BMMw.
By Northern and Western analysis performed on virally
infected BMMw derived from PKR2/2 or RNaseL2/2
strains, we found that neither PKR nor RNaseL were re-
quired for IFN-g–induced decreases in viral IE1 mRNA or
protein levels (data not shown).
Discussion
In this paper we demonstrate the following important
points: (a) IFN-g is much more effective at blocking
MCMV replication in primary BMMw than MEFs, (b)
IFN-g action in BMMw does not require known media-
tors of antiviral effects of IFN, (c) the mechanisms of action
of IFN-g differ significantly in BMMw and MEFs, and (d)
IFN-g acts by a novel mechanism, independent of RNaseL
and PKR, to decrease IE1 protein expression in BMMw.
Although IFN-g–induced activation of STAT-1a is similar
in BMMw and MEFs early after IFN-g treatment, microar-
ray analysis showed that IFN-g regulated gene expression
differently in BMMw and MEFs. Thus, IFN-g may act in
different primary cells types by inducing or decreasing ex-
pression of different sets of genes. The fact that IFN-g ac-
tion is cell type specific and utilizes a novel mechanism in
BMMw, a cell type key for both acute and chronic MCMV
infection, has important implications for understanding
how IFNs regulate viral infection.
The Role of IFN-g in Cytomegalovirus Infection and the
Importance of Defining Antiviral Mechanisms of IFN-g against
CMV. The role of IFN-g in cytomegalovirus infection is
controversial, with published studies arguing for a role of
IFN-g in either inhibiting or promoting infection. Some
evidence has been presented for a role for IFN-g enhanc-
ing infection with rat CMV in vivo (65), and for a role of
high dose exogenously administered IFN-g enhancing
MCMV disease (3). However, multiple groups have con-
vincingly demonstrated a protective effect of IFN-g at
multiple stages of cytomegalovirus (both rat and mouse
CMV) infection, including acute infection (1, 3, 6, 7, 65),
prevention of chronic persistent infection (4, 5), induction
of effective antigen presentation (5, 66), and inhibition of
reactivation from latency (7, 10). We have additionally
shown that IFN-g plays an important role in protection
against vascular disease induced by either MCMV or the
g-herpes virus gHV68 (7, 67).
Although these studies all argue for a protective role for
IFN-g against MCMV infection, in humans IFN-g is in-
volved in differentiation of peripheral blood mononuclear
cells into Mw that are permissive for human CMV replica-
tion (HCMV [68]). In these studies, IFN-g was added to
freshly isolated adherent human PBMCs and 9 d later cul-
tures were infected with HCMV. Under these conditions,
IFN-g resulted in Mw that replicated HCMV very effi-
ciently. This is in striking contrast to the results we present
here in which pretreatment of already differentiated cells
with IFN-g inhibited replication 100-fold. We feel it likely
that these differences reflect the fact that we add IFN-g be-
fore infection of already differentiated cells, whereas in the
studies by Soderberg-Naucler et al. (68), IFN-g is added
during the differentiation process. An argument was made
by Soderberg-Naucler et al. that IFN-g does not have anti-
viral activity in differentiated human Mw, as treatment of
cultures with IFN-g after HCMV infection did not inhibit
replication of the virus (68). However, this conclusion is
unlikely, as IFN-g typically requires induction of gene ex-
pression to exert its effects, and thus pretreatment with
IFNs is often required to observe maximal antiviral effects.
Moreover, both HCMV and MCMV specifically inhibit
IFN signaling (34, 69–71). Thus, one would not expect
IFN-g to effectively inhibit CMV infection when added
after viral infection. Notwithstanding this caveat, it is clear
that under some conditions IFN-g can generate cells that
efficiently replicate HCMV. In this regard, it is notable that
MCMV replicates well in cells derived from IFN-gR2/2
mice (Fig. 3 A) and can reactivate from BMMw derived
from latently infected IFN-gR2/2 mice (7), demonstrating
that IFN-g is not required for differentiation of permissive
Mw in vivo.
Although IFN-g can influence Mw differentiation, re-
sulting in HCMV permissive cells, other investigators have
shown that IFN-g has antiviral effects against HCMV. Hu-
man CD4 T cells, which play an important role in control-
ling HCMV infection (72), secrete IFN-g (15). When the
astrocytoma line, U373MG, (15) or human fibroblasts (73)
are preincubated with IFN-g, significant inhibition of
HCMV replication and expression of early and late gene
products is observed, a result consistent with our findings as
well as previous studies showing that pretreatment with
IFN-g inhibits MCMV replication in fibroblasts (11, 13).492 Cell Type–specific IFN-g Antiviral Mechanism in Mw
Interestingly, and similar to studies presented here, evi-
dence was presented in one study supporting an effect of
IFN-g on expression of HCMV IE proteins (15).
Despite this, the mechanism of IFN-g action against
MCMV has been controversial. Conclusions based on
work in infected primary (11) or transformed fibroblasts
(13) have been contradictory with the proposal that IFN-g
targets either IE mRNA expression (13) or late mRNA ex-
pression (11). Experiments presented here help to clarify
this conflict, as we found that the effects of IFN-g are cell
type specific with actions on the IE stage of MCMV repli-
cation in BMMw compared with actions on the late stage
of infection in MEFs. Effects of IFN on the IE stage of
MCMV infection are strikingly similar to mechanisms of
action against HSV-1 (74).
Potential Consequences of Cell Type Specificity. We show
here that IFN-g has cell type–specific effects against
MCMV infection in vitro. This may be a generally applica-
ble finding. IFN-g has cell type–specific effects in vivo
against LCMV infection. IFN-g treatment clears hepato-
cyte infection, but not intrahepatic nonparenchymal cells
or splenocytes (75). Fibroblasts and Mw likely play distinct
roles in the replication and pathogenesis of MCMV in
vivo. Mw have been shown to harbor latent virus (27–29).
They have also been implicated in spread of the virus (20–
23), and play an important role in determining the out-
come of MCMV disease (25, 26). Fibroblasts are more
likely to play a role in the initial acute infection. Thus, the
cell type specificity of IFN-g action in BMMw versus
MEFs is likely to play a role in its function in vivo. Indeed,
IFN-g has been shown to play a key role in terminating
persistent viral infection of both MCMV and other viruses
(4, 5, 7, 76, 77). As Mw are a likely latent reservoir for
MCMV, blockade to viral growth in these cells may ex-
plain why IFN-g plays a strong role in protecting the host
against reactivation both in vitro (7) and in vivo (10). Its
protective effect in Mw is likely to aid in maintaining anti-
gen presentation in light of multiple viral mechanisms
which inhibit both the class I and class II pathways (34, 78–
80). IFN-g has been shown to restore antigen presentation
in the setting of viral infection (5, 66). Thus, the effective-
ness of IFN-g against MCMV replication in Mw may have
important consequences for the course of pathogenesis and
disease in infected mice.
Potential Mediators of IFN-g Effects on MCMV Growth and
IE1 Protein Expression. We found that the well-character-
ized potential effector mechanisms for IFN-g including
IFN-a/b receptors, PKR, iNOS, TNF-a receptors, Mx1,
and RNaseL are not required for IFN-g–mediated inhibi-
tion of MCMV growth in BMMw. However, IFN-g ac-
tion in BMMw does require the IFN-g receptor and
STAT-1, acts in cis in the infected cell rather than by in-
ducing expression of additional soluble mediators, and tar-
gets a specific stage in MCMV replication. The existence of
as yet undiscovered antiviral mechanisms of IFN is also
suggested by residual IFN-a/b effects against encepha-
lomyocarditis virus in mice triply deficient for Mx1, PKR,
and RNaseL (81). These alternative mechanisms may be
required by the host because viruses have evolved strategies
for inhibiting certain pathways of IFN action. By using
multiple antiviral mechanisms specifically targeted to vul-
nerable stages in the replication cycle of specific viruses, the
host may be able to overcome immune evasion by viruses.
Many viruses, particularly those which persist in the host,
have developed mechanisms to block the effectiveness of
interferons, including inhibition of PKR (82, 83) and dis-
ruption of the Janus kinase (JAK)/STAT pathway (69, 70,
84). Considering the lack of a requirement for PKR or
RNaseL in the antiviral effects of IFN-g against MCMV, it
is tempting to postulate that MCMV may also inhibit these
pathways. It has already been reported that one down-
stream function of IFN-g, induction of MHC class II, is in-
hibited by CMV infection (34, 71).
Although we have identified one target of IFN-g action
against MCMV in BMMw (expression of the IE1 protein),
the molecular pathways involved are not defined. The dif-
ferent transcriptional responses to IFN-g in BMMw versus
MEFs could provide a starting point for identification of
molecules responsible for the effects of IFN-g. If the stages
of MCMV infection are the same in BMMw and MEFs, it
seems unlikely that genes which are similarly regulated in
BMMw and MEFs will explain cell type–specific effects of
IFN-g. However, it is possible that a difference in the
stages of MCMV infection in BMMw as opposed to MEFs
could provide a target for an IFN-g–induced gene in one
cell type and not the other.
There are several possibilities for the mechanism of IFN-g
action worth noting. It has been reported that IFN-g in-
hibits IE gene transcription by downregulating nuclear fac-
tor (NF)kB activity (85). The interferon inducible protein,
p202, can modulate transcription by binding NFkB sites
(86), and may therefore be involved in this mechanism. In
support of this hypothesis, a family member of p202, the
human IFN-inducible protein IFI16, has been shown to
repress transcription of the HCMV UL54 promoter (87).
Although we only observed decreased IE1 mRNA during
the first few hours of infection, it will be interesting to
evaluate whether this mechanism may be playing a role in
the effect of IFN-g seen in Mw infection. A second alter-
native mechanism involves the indoleamine 2,3 dioxygen-
ase (IDO) pathway. In retinal pigment epithelial cells, IFN-g
inhibits HCMV replication, and the effects of IFN-g are
reversed by addition of l-tryptophan, an inhibitor of IDO
(88). However, preliminary studies in our lab suggest that
the IDO pathway is not involved in BMMw-specific IFN-
g–mediated protection, as neither the addition of l-tryp-
tophan nor a specific inhibitor of IDO, 1-methyl tryp-
tophan, reversed IFN-g–mediated inhibition of MCMV
growth. A third potential mediator of IFN-g effects in
BMMw is IFN-g regulation of cell cycle. Cell cycle regula-
tion by herpes viruses is a critical part of the viral life cycle
(for reviews, see references 89 and 90–96). IFN-g treat-
ment of BMMw with IFN-g results in expression of p21waf-1,
leading to arrest at the G1/S boundary (97). As the out-
come of MCMV infection is dependent on cell cycle phase
(94), IFN-g’s effects on the cell cycle may influence CMV493 Presti et al.
infection. It is possible that differences in the effectiveness
of IFN-g in BMMw and MEFs reflect differences in prolif-
erative capacity or cell cycle regulation between these two
primary cell types. An interesting additional potential
mechanism of IFN-g action has been recently identified in
hepatitis B virus (HBV) transgenic mice. HBV gene ex-
pression in these mice is down regulated by a posttranscrip-
tional mechanism induced by IFN-g and TNF-a (98). Re-
cent data suggests that this is mediated by the La protein, an
RNA binding protein which is associated with clearance of
HBV viral RNA (99, 100). These mechanisms will need to
be evaluated in the MCMV system and compared between
primary MEF and BMMw. Further analysis of the specific
molecules involved in the novel Mw-specific mechanism of
IFN-g action demonstrated here may well lead to defini-
tion of novel pathways of IFN action.
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